THBS1 inhibitor, LSKL, could significantly reduce ECM remodeling induced by macrophage-fibroblast interaction during TB, suggesting that targeting THBS1 could be a novel approach for TB treatment. The gene discussed is THBS1; the disease is tuberculosis.